# DiaMonTech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/diamontech

- Industry: Medical Devices & Equipment
- Headquarters: Berlin, Germany
- Website: www.diamontech.de
- Total disclosed funding: $7.7M
- Latest round: Series A (Sep 9, 2019)
- Investors on record: 3

## About

Based in Germany, DiaMonTech AG is a developer of non-invasive blood glucose monitoring solutions, aiming to improve the quality of life for diabetes patients through innovative technology.DiaMonTech AG, founded in 2015 in Berlin, Germany, specializes in creating advanced non-invasive blood glucose monitoring devices. The company was co-founded by Rainer Gith, Thorsten Lubinski, and Werner Mäntele. In September 2025, DiaMonTech AG raised EUR 8 million in venture funding led by new investor Companisto, with participation from another new investor Samsung NEXT Ventures. Individual and other unspecified investors also participated in the round. DiaMonTech specializes in the development of non-invasive blood glucose monitoring solutions. Their core offering includes a compact blood glucose meter designed to provide precise and pain-free glucose measurements within seconds. This device utilizes patented technology that is still in development, aiming to enhance the quality of life for individuals living with diabetes. The company collaborates with partners, including Samsung, to develop a miniaturized sensor that can be integrated into wearable devices such as smartwatches. The primary end users of these products are individuals with diabetes, healthcare providers, and researchers in the biosciences sector. While based in Berlin, their innovative solutions are intended for broader geographical markets beyond just Germany. The revenue model for DiaMonTech centers around the commercialization of its non-invasive blood glucose monitoring technology, which is expected to generate income through direct-to-consumer sales and partnerships with health technology companies. As their flagship product develops, the company plans to implement a subscription model for their accompanying app, which will track blood glucose levels, blood pressure, nutrition, activity, and medication management. This app may integrate with other health applications, thus expanding its utility among consumers. Although specific pricing plans have not been detailed, strategic partnerships with major companies like Samsung indicate potential for B2B agreements that could include product integration and distribution across various health and wellness platforms. The company plans to utilize the September 2025 funding toward entering markets in Europe and the US, in addition to obtaining regulatory approvals.

## Funding rounds

- Series A, Sep 9, 2019, $7.7M — IBB Ventures, YuanBio Venture
- Seed, Jan 1, 2017 — Media Ventures

## Investors

- Media Ventures (https://capitalatlas.ai/funds/media-ventures) — Seed
- IBB Ventures (https://capitalatlas.ai/funds/ibb-ventures) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A